ReviewAntibiotics (Basel, Switzerland)2025
New Perspectives in the Fight Against Multidrug-Resistant Bacteria: The Potential of Endolysin Biocomposites.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Endolysin Activity Using Nephelometric Assays with Whole Bacterial Cells and Isolated Peptidoglycan.Methods in molecular biology (Clifton, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The growing threat of multidrug-resistant bacteria requires innovative therapies beyond traditional antibiotics. This review highlights the potential of endolysin biocomposites using alginate oligosaccharides (AOSs) and modified cellulose (CL) as stabilizers. AOSs could enhance endolysin stability and potentially support colonic fermentation, producing short-chain fatty acids that may synergize with endolysins to combat pathogens and improve gut health. KZ144 and LysPA26 are proposed as optimal candidates for their broad pH range, divalent cation tolerance, and potential effectiveness against Gram-positive and Gram-negative pathogens. Integrating AOSs and CL into biocomposites could offer a novel dual-action strategy against gastrointestinal diseases while potentially reducing antibiotic dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.